Goldman Sachs upgrades IBM (IBM) to Buy
Goldman Sachs upgraded IBM from Neutral to Buy and raises its price target to $195.
Goldman Sachs upgraded Johnson & Johnson from Neutral to Buy, while downgrading Bristol-Myers Squibb Co..